Loading stock data…
ELVN
$41.70+0.47 (+1.14%)
After Hours$42.50+0.80 (+1.92%)· Last close May 1
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Enliven Therapeutics, Inc. in the Healthcare sector is trading at $41.70. The stock is currently 14% below its 52-week high of $48.53, remaining 67.5% above its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why ELVN maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$41.70
Potential Upside
5%
Whystock Fair Value$43.79
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor whi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.66B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.56%
Volume
Today's trading volume
447,584
Recent News
Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market
Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 11 Stocks With 3x-5x Returns This Year. Enliven Therapeutics has seen its stock price soar by 194 percent year-to-date, at $45.34 versus $15.40 on December 31, with investor sentiment primarily bolstered by the growing interest in the chronic myeloid leukemia (CML) treatment market following its competitor’s merger […]
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $48 to $56 and kept its Buy rating on the stock. This increase in valuation came after Merck & Co., Inc. […]
Assessing Enliven Therapeutics (ELVN) Valuation After Strong Recent Share Price Momentum
Enliven Therapeutics (ELVN) has drawn fresh attention after recent trading left the stock around $38.83, with a market value near $2.32b. This has prompted investors to reassess its profile as a clinical-stage cancer drug developer. See our latest analysis for Enliven Therapeutics. That recent move to $38.83 comes after a 149.87% year to date share price return and a 143.60% 90 day share price return, while the 1 year total shareholder return sits at 84.29%. This suggests momentum has been...
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million
This Boulder-based biotech, developing targeted cancer therapies, reported a notable insider sale as Phase 1 trials advance for key drug candidates.
Enliven Therapeutics (ELVN) Soars to 5-Year High as Analysts ‘Upbeat’
Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 10 Stocks Investors Are Buying Now. Enliven Therapeutics soared to a new five-year high on Wednesday, as investors took heart from two analysts’ optimistic coverage for the stock, with one raising its price target by 9.7 percent. In intra-day trading, the stock climbed to a record high […]